Miconazole for treatment of disseminated coccidioidomycosis. Unfavorable experience.
Miconazole at dosages up to 30 mg/kg/day was given intravenously to seven patients with complicated courses of disseminated coccidioidomycosis. Six had received treatment with amphotericin B previously and five of these patients could be evaluated for the efficacy of the treatment. In three patients the condition failed to respond to therapy, another patient required intratracheal administration of amphotericin B later, and the fifth patient had an equivocal response to treatment. Severe phlebitis, pruritus, nausea, vomiting, hyperlipidemia, and thrombocytosis were frequent side effects. These limited unfavorable results indicate that until controlled studies demonstrate its safety and efficacy, therapy with miconazole should be reserved for highly selected patients with disseminated coccidioidomycosis who cannot receive amphotericin B.
D000328:Adult; D000666:Amphotericin B / Q000008:administration & dosage / Q000627:therapeutic use; D003047:Coccidioidomycosis / Q000188:drug therapy*; D004341:Drug Evaluation; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D007263:Infusions, Parenteral; D007276:Injections, Intraventricular; D008172:Lung Diseases, Fungal / Q000188:drug therapy; D008297:Male; D008581:Meningitis / Q000188:drug therapy; D008825:Miconazole / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged
D007093:Imidazoles; D008825:Miconazole; D000666:Amphotericin B